102 related articles for article (PubMed ID: 11361794)
21. Combination shows reduction in viral levels.
AIDS Patient Care STDS; 1996 Jun; 10(3):184. PubMed ID: 11361623
[No Abstract] [Full Text] [Related]
22. 141 (Vertex-478).
Baker R; Bowers M
BETA; 1997 Mar; ():5. PubMed ID: 11364529
[TBL] [Abstract][Full Text] [Related]
23. Ritonavir pediatric study results reported.
AIDS Patient Care STDS; 1998 Jan; 12(1):63. PubMed ID: 11361889
[No Abstract] [Full Text] [Related]
24. Nelfinavir at six months.
PI Perspect; 1997 Mar; (No 21):11-2. PubMed ID: 11364207
[TBL] [Abstract][Full Text] [Related]
25. Update on antivirals.
PI Perspect; 1996 Sep; (No 19):7-9. PubMed ID: 11363906
[TBL] [Abstract][Full Text] [Related]
26. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
27. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
[TBL] [Abstract][Full Text] [Related]
28. Amping amprenavir with ritonavir.
TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
[No Abstract] [Full Text] [Related]
29. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
30. [HIV: to administer protease inhibitors early].
Dtsch Med Wochenschr; 1996 Dec; 121(49):A49. PubMed ID: 8998916
[No Abstract] [Full Text] [Related]
31. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs].
Jensen-Fangel S; Larsen L; Thomsen HF; Nielsen LP; Black FT; Obel N
Ugeskr Laeger; 1999 Mar; 161(12):1751-4. PubMed ID: 10210974
[TBL] [Abstract][Full Text] [Related]
33. Anti-HIV agents. Indinavir--3 years and still going strong.
TreatmentUpdate; 2000 Sep; 12(6):3-4. PubMed ID: 12132460
[No Abstract] [Full Text] [Related]
34. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
Benard A; van Sighem A; Taieb A; Valadas E; Ruelle J; Soriano V; Calmy A; Balotta C; Damond F; Brun-Vezinet F; Chene G; Matheron S;
Clin Infect Dis; 2011 May; 52(10):1257-66. PubMed ID: 21507923
[TBL] [Abstract][Full Text] [Related]
35. New drugs: amprenavir and abacavir.
TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
[TBL] [Abstract][Full Text] [Related]
36. Final CESARE trial results show continued clinical and survival benefit.
AIDS Patient Care STDS; 1997 Apr; 11(2):96. PubMed ID: 11361772
[No Abstract] [Full Text] [Related]
37. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
[TBL] [Abstract][Full Text] [Related]
38. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
[TBL] [Abstract][Full Text] [Related]
39. Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.
Arribas J; Pulido F; Hill A; Delft Yv; Moecklinghoff C
Int J STD AIDS; 2013 Aug; 24(8):679-81. PubMed ID: 24014249
[No Abstract] [Full Text] [Related]
40. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
